1080 results about "Food intake" patented technology

A diabetes management system and method used to manage the blood glucose level of a diabetes patient. The system includes at least one portable electronic device and a database system. The portable electronic device allows the patient to input different types of data into the processor to calculate insulin and carbohydrate intake recommendations for the patient. A time / date stamp is individually generated and stored for each type of data inputted by the patient. The diabetes management system also includes a database system which stores (i) activity data associated with the physical activity of the patient, (ii) blood glucose data associated with the blood glucose level of the patient, (iii) meal intake data associated with the food intake of the patient, and (iv) insulin intake data associated with the insulin intake of the patient.

Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.

The present invention relates to methods and devices that help to curb appetite and / or reduce food intake. In one embodiment, the methods and devices of the present invention include a small intestinal / duodenal insert comprising an elongated member with at least one flow reduction element that can cause the stimulation of one or more biological signals of satiety.

A method for the treatment of obesity or other disorders, by wireless electrical activation or inhibition of the sympathetic nervous system. This activation or inhibition can be accomplished by wirelessly stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using a wireless electrode inductively coupled with a radiofrequency field. The source of radiofrequency energy may be internal or external to the patient. This nerve activation can result in reduced food intake and increased energy expenditure.

Novel exendin and exendin agonist compound formulations and dosages and methods of administration thereof are provided. These compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and / or slowing gastric emptying or inhibiting food intake.

The present invention relates to a treatment of obesity, and in particular to a therapeutic method belonging to a surgical field for obesity wherein it is possible to reduce a calorie intake amount and to lose weight using a gastroscope used for endoscopic examination of the stomach in such a manner that a certain balloon is inserted in the interior of stomach of fat person for thereby decreasing the entire volume of stomach, so that a user feels a earlier fullness during eating food thus decreasing the amount of food intake.

The invention relates to a controlled release bait material and a preparation method thereof. The controlled release bait material refers to small pills, micro-pills, microcapsules, microspheres, particles or sticks prepared from raw materials including a basic material, a feed attractant, a bonding agent, a hydrophilic high-polymer material, a water-insoluble high-polymer material, a quick-release material, a filler, a colorant, a flavoring agent and the like through a preparation means; and the controlled release bait material can be coated for improving the controlled release effect. The invention further discloses a preparation method of the bait material. The controlled release material has rapid and lasting attracting force on fishes, the fish attracting time can be adjusted according to the habit of a fisherman and the habits of fishes, the food ration and frequency of fishes are increased, the fishing success rate can be increased, the food intake of fishes in cultivation of fishes can be increased, the corrosion ratios of remnant feeds and feeds in water bodies are reduced, the utilization ratios of feeds is increased, and the water body environmental pollution is lowered. The preparation method provided by the invention is suitable for industrial production.

The invention relates to the extraction and / or presentation of glucose concentrations estimated as a function of time into a format that facilitates conveyance of the underlying information. More particularly, short term actions, such as exercise, diabetes drug treatment, and / or food intake, are correlated to glucose response profiles. Optionally, glucose concentration responses are back correlated to parameters, such as time, exercise, diabetes drug treatment and / or food intake. The resulting correlated data are output to the user in a time compressed format, in video format, and / or as a cluster allowing diagnosis and treatment information to be more readily determined and used. These information presentations are useful for both the medical professional and the end user. The information presentation is preferably used with a noninvasive, implantable, semi-continuous, and / or continuous analyte analyzer, such as a glucose concentration analyzer.

The present invention is concerned with compounds of the general Formula I: and pharmaceutically acceptable salts thereof, which are useful as melanin concentrating hormone receptor antagonists, particularly MCH-1R antagonists. As such, compounds of the present invention are useful for the treatment or prevention of obesity or eating disorders associated with excessive food intake and complications thereof, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), mental disorders stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Compounds of formula I may therefore be used in the treatment of these conditions, and in the manufacture of a medicament useful in treating these conditions. Pharmaceutical formulations comprising one of the compounds of formula (I) as an active ingredient are disclosed, as are processes for preparing these compounds.

The present invention relates to devices and methods of operating the devices that contribute to curbing appetite and / or reducing food intake. In some embodiments, the methods and devices of the present invention include as intestinal / duodenal insert comprising an elongated member with at least one flow reduction element that can cause the stimulation of one or more biological signals of satiety. Some embodiments of the inserted device are anchored at the duodenal site by an anchoring member residing in the stomach, other embodiments of the device are stabilized at a targeted site by appropriate dimensions of length as well as one or more angled portions of the device that correspond to angled portions of the targeted site in the dodenum. Embodiments of the device exert effects by virtue of physical presence, as well as by more active forms of intervention, including release of bioactive materials and electrical stimulation of neurons.

A portable diabetes management device calculates medication dosages from glucometer readings and data such as food intake entered by the patient, according to a management plan that can be personalized by a health-care professional using a template. The device may also store and communicate past data and plan revisions.

A food intake restriction device for forming a restriction in a patient's gastro-intestinal tract and non-invasively communicating pressure data regarding the restriction to an external monitor. The device includes a food intake restriction device implanted substantially about a patient's gastro-intestinal tract to form a restricted opening in the tract. A port is connected to the restriction device. The port contains a working fluid for affecting the size of the restricted opening. A pressure sensing system communicates with the working fluid to measure the pressure of the working fluid. A transmitter communicates the measured fluid pressure to the external monitor.

A bi-directional communication system for use with a restrictive opening device implanted within a patient. The system includes a sensor for measuring an operational parameter within the restrictive opening device. The system further includes a means for communicating a measured parameter data from the sensor means to a local unit external to the patient. The system further includes a base unit at a remote location from the patient, the base unit including user interface means for evaluating the measured parameter data. And, a communication link between the local and base units for transmitting data between the units, the transmitted data including the measured parameter data.

A method for the treatment of obesity or other disorders by electrical activation or inhibition of the sympathetic nervous system is disclosed. This activation or inhibition can be accomplished by stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an electrode. This nerve activation can result in reduced food intake and increased energy expenditure.

Provided herein is a method for monitoring dietary intake of food items. The method involves the steps of selecting a portion of food, weighing the portion, inputting the type and weight amount of the food into a computer, and obtaining the caloric content of the food by from a database. There is also provided an apparatus for monitoring dietary intake of food items. The apparatus includes a means for weighing a preselected portion of food, a computer for inputting the type and weight amount of the food therein, and a database operatively associated with the computer for obtaining the caloric content of the food.

A system is disclosed for monitoring a property of an ingested or in-taken drug, food, drink or toxic substance, non-invasively or minimally invasively, which can also identify the subject person being monitored, if desired. The system comprises: a means of labeling the substance with a labeling media to have a useful signature indicative of, or bearing a relation to the property; a means to allow the signature to be read non-invasively or minimally invasively; and a means to identify, in any manner, who is being monitored.

A portable device which utilizes a method for tracking consumption of food calories, carbohydrates, fats, or proteins using a cell phone, personal data assistant, or hand held device. The user can record food intake; calculate basal metabolic rate; daily caloric needs; monitor calories, carbohydrates, protein or fats; and provide current metabolic state with corresponding exercise for weight control. The user can enter a timed physical activity to determine caloric balance between calories eaten and calories burned. Data is displayed for 7, 14, or 30 days, and can be Emailed to and synchronized with the user's personal computer or internet server

This invention relates to the identification of fatty acid or lipid amides that decrease food intake in mammals, including fatty acid ethanolamides, as ligands for the G-protein coupled receptor OSGPR116, and describes the first demonstration of a specific G-protein coupled receptor that is activated by fatty acid ethanolamides that inhibit feeding. The invention is directed to new methods for screening candidate drugs for their ability to modulate the activity of OSGPR116, and new pharmaceutical agents identified by these methods. It is also directed to the use of such agents in the manufacture of medicaments for the treatment of OSGPR116 mediated diseases, and methods of treating diseases such as obesity and diabetes by administering to an individual a therapeutic amount of a modulator of OSGPR116 identified by these methods.

The present invention uses market research data to access nutrient intakes of a population. Dietary collection using 24-hour recall generally does not reflect a pattern of “usual” intake behavior for a population group. To determine the impact of food consumption patterns on nutrient intake, a unique methodology using 14-day food diary was developed. The food industry has traditionally used detailed food records to track the consumption of specific branded food items and monitor the growth of food categories, but some of the most valuable databases available concerning longer-term (e.g., 14-day) food intake do not record portion size on an individual consumption basis. Other databases based on shorter-term (24-hour recall) survey periods record portion sizes but are not very representative of eating habits. The preferred exemplary embodiment integrates two such databases with a third data set providing detailed nutrient information for each of a wide variety of foods consumed to provide a combined database for processing nutrient intake reports using statistical analysis. This flexible system allows the user to categorize the population based on “usual” consumption of food categories, specific foods and / or specific brands of foods and determine dietary differences versus their “non-using” counterparts.

The present invention relates to novel inhibitors of glutaminyl cyclase and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia.

A system for managing the food intake of a person comprises means for collecting information about food consumed by the subject, and means for providing feedback to the subject regarding the food consumed. It further comprises a sensor (57) for obtaining a signal related to the person and monitoring means for generating the information by performing a pattern recognition of the obtained signal for detecting whether the person is consuming food. The sensor comprises a camera and the pattern recognition comprises image processing. The image processing comprises the detection of a mouth and of a hand and of food. The system further comprises means for causing an audio / video-rendering device (56) to deliver the feedback. The camera is attached to the rendering device. The system further comprises means for identifying available rendering devices (56) arranged for being caused to deliver feedback.

The present invention relates to a composition for treating obesity-related diseases comprising an insulinotropic peptide conjugate, more particularly, to a composition for treating obesity-related diseases comprising a conjugate prepared by covalently linking the insulinotropic peptide with a carrier substance via a non-peptidyl linker, and a method for treating obesity-related diseases by using the same. In particular, the composition for treating obesity-related diseases according to the present invention remarkably improves the efficacy of suppressing food intake and its duration to reduce body weight and body fat, thereby being useful for the treatment of obesity-related diseases.

The present invention is concerned with compounds of the general Formula I: and pharmaceutically acceptable salts thereof, which are useful as melanin concentrating hormone receptor antagonists, particularly MCH-1R antagonists. As such, compounds of the present invention are useful for the treatment or prevention of obesity or eating disorders associated with excessive food intake and complications thereof, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), mental disorders stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Compounds of formula I may therefore be used in the treatment of these conditions, and in the manufacture of a medicament useful in treating these conditions. Pharmaceutical formulations comprising one of the compounds of formula (I) as an active ingredient are disclosed, as are processes for preparing these compounds.

This invention addresses the problem of how to separately regulate the food intake of multiple animals using the same feeder with the goal of maintaining healthy weight for all. The invention provides a means to prevent access to the feeder by animals that have exceeded their allowance (as dictated by programmable profiles) as well as preventing unauthorized animals (such as excluded pets, wild animals or animals on a special diet). The methods can be applied to a broad range of feeders: for domestic pets, livestock, zoo animals and other managed animals. The invention is particularly well suited to dry food gravity feeders. The invention details electronic and electro-mechanical embodiments of devices intended for the described purpose.

The invention provides methods and devices to sense food intake, and parameters such as glucose concentration that change as a function of food intake, in a patient. The invention provides for measurement of physiological parameters that change as a function of food intake, such as a core body temperature. Some embodiments of the invention also measure activity of the patient. The invention may further provide methods and devices to provide treatment for medical conditions related to food intake, such as delivery of insulin or other substance to regulate the blood glucose of the patient.

The present invention provides a composition (e.g., a pharmaceutical composition) comprising at least one delivery agent compound and at least one of peptide YY (PYY) and a PYY agonist. Preferably, the composition includes a therapeutically effective amount of peptide YY or the PYY agonist and the delivery agent compound. The composition of the present invention facilitates the delivery of PYY, a PYY agonist, or a mixture thereof and increases its bioavailability compared to administration without the delivery agent compound. PPY and PYY agonists possess activity as agents to reduce nutrient availability, including reduction of food intake.

A method for treating eating disorders comprising the steps of generating a neuro-electrical satiety signal that substantially corresponds to a neuro-electrical signal that is generated in a body and produces a satiety effect in the body, sensing food intake in a subject over at least a first period of time, and transmitting the neuro-electrical satiety signal to the subject if the food intake of the subject exceeds a predetermined threshold level during the first period of time.

The invention relates to devices that are stabilized at an intraluminal residence site in the gastrointestinal tract by their conformation, including dimensions of length and curvature. The device as a whole corresponds to the conformation of the residence site; more particularly, the curved or angled portions correspond to the curved or angled portions of the residence site and do not conform to an immediately proximal or distal site. In some embodiments, the conformationally stabilized device may effect a change in the residence site shape that contributes to stability of the device. Some embodiments are directed toward curbing appetite and / or reducing food intake, other embodiments may be directed toward other therapeutic ends. Some embodiments of the device are designed to reside wholly in the duodenum; others reside principally within the duodenum but extend proximally into the gastric antrum, while other embodiments are designed to reside elsewhere within the gastrointestinal tract.